openPR Logo
Press release

Global Companion Diagnostics Market

06-26-2017 04:39 PM CET | Health & Medicine

Press release from: Clinical Diagnostic Report By CMI

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test products.
The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks. AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion diagnostics in treating chronic diseases.

Request a sample copy of this report@

Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.

Ask for Discount before buying the Report@

Key take aways of the global companion diagnostics market:
The global companion diagnostics market is expected to expand at a CAGR of 12% during the forecast period (2016–2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally
The breast cancer application in the global companion diagnostics market was estimated to be the largest in 2015 and is expected to dominate the companion diagnostics market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer.

In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies.
The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in companion diagnostics market has increased from 13 in 2007 to 66 in 2013.
Some of the major players in the global companion diagnostics market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare

Get More Details about this Report@

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Visit Coherent Market Insights Blog @
Connect with us on LinkedIn @

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Companion Diagnostics Market here

News-ID: 593660 • Views:

More Releases from Clinical Diagnostic Report By CMI

Sepsis Diagnostic Market-Global Industry Insights, Trends, Outlook
Sepsis Diagnostic Market-Global Industry Insights, Trends, Outlook
Sepsis is life threatening complication caused due to the infection, which can result into organ failure, tissue damage, and ultimately lead to death if left untreated. If sepsis progresses to septic shock, it cause sudden drop in blood pressure and may leads to death of patient. Sepsis occurs due the infection in any part of the body. However the most common site of infections leading to the sepsis are lungs,
Liquid Biopsy Market - Insights
Liquid biopsy involves testing of the blood to identify biomarkers or cancer cells in the form of cells or pieces of DNA which are separated from the tumor and are circulating in the blood. Liquid biopsy helps in early detection of cancer, which would aid in adopting an optimal treatment plan. It is a non-invasive technique, which makes frequent testing possible, and effectiveness of cancer treatment can also be validated
Enteric Disease Testing Market - Global Industry Insights 2025
Enteric Disease Testing Market - Global Industry Insights 2025
Enteric infection is a type of intestinal disease that causes symptoms ranging from mild gastroenteritis to systemic infections and severe diarrhea. According to WHO in 2017, Infectious gastroenteritis accounts for 1 billion cases of diarrhea globally and over 2 million deaths annually. In addition to this, according to Bill and Melinda Gates Foundation, 2017, enteric and diarrheal diseases leads to death of about 500,000 children, under the age of five
Hospital Acquired Disease Testing Market to Surpass US$ 2.7 Billion by 2025 Globally, with Favorable Reimbursement Policies and Supporting Initiatives
Hospital Acquired Disease Testing Market to Surpass US$ 2.7 Billion by 2025 Glob …
Hospital acquired Disease Testing – Hospital or Mortuary Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients occurred due to adverse reaction caused by infectious toxin agents under medical care and were absent at the time of admission. Hospitals acquired infections results in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and increase mortality rate. Pathogens responsible for nosocomial infections include viruses, fungal parasites, and bacteria. Hospital acquired

All 5 Releases

More Releases for CDx

Companion Diagnostic (CDx) Market Outlook & Growth Prediction 2022 By Leading Pl …
Stratagem Market Insights recently published a research report titled, "Companion Diagnostic (CDx) Market - Increase in Demand and Opportunities 2022". The research report attempts to give a holistic overview of the Companion Diagnostic (CDx) market by keeping the information simple, relevant, accurate, and to the point. The research report highlights the inner and outer examination of the Companion Diagnostic (CDx) market. This intelligence report includes investigations based on Current scenarios,
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Pharmacogenomics Technology
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market survey report has been prepared by conducting market research in a
Pharmacogenomics Technology (Theranostics & Cdx) Market 2021 Analysis by Size, S …
This comprehensive Report on the Pharmacogenomics Technology (Theranostics & Cdx) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. It represents a comprehensive and succinct analysis report of the main competitor and price statistics with a view to helping beginners establish their
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Mark …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by companies, region, type and end-use industry. Get Sample Copy of This Report @ In 2017, the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size was million US$ and it is expected to reach million US$ by the end of 2025,
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Sale …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, analyzes and researches the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Qiagen NV GE Healthcare Agilent Technologies F Hoffman La Roche Foundation Medicine Thermo Fisher Scientific Inc. Leica Biosystems Nussloch GmBH Pfizer Get the sample copy of report : Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast